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the prediction of trabectedin sensitivity. Although this was a
small retrospective study, it showed that DNA repair gene expres-
sion patterns can predict the sensitivity of sarcoma patients to
trabectedin.
A potential design for a pivotal phase II trial for a given drug in
a particular tumour type based on a molecular signature is
described in Fig. 1.
CONCLUSION: The identification of molecular signatures corre-
lating with tumour vulnerability to anticancer agents is instru-
mental in the era of molecular medicine. Such molecular
signatures are expected to be trans-tumoural and thus applicable
for predicting sensitivity to a given drug in a set of other malig-
nancies. This approach could have a positive influence on devel-
opment time and costs, pharmacoeconomics, success rates in
pivotal studies, the pharmaceutical industry’s business models,
and—most important—the well-being of cancer patients. Imple-
menting such a framework would require a close interaction of
academia, regulatory agencies, patient organizations and
industry.
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Much can be gained through innovative thinking and methods
during the early phases (I and II) of drug development, which
are largely exploratory in nature. Phase III, however, should be
confirmatory.
There are several potential problems associated with adap-
tive or flexible designs that can pose risk to the integrity and
credibility of a trial. For example, breaking the blind early can
lead to problems with dissemination of study results and the
study population might change between the early and late
stages of drug testing. Regulators tend to be wary if the scientific
question is not clear which will lead to difficulties with inter-
preting the outcome results. The overarching problem, from a
regulatory point of view, is overemphasis on statistical signifi-
cance rather than on clinical relevance. Maintaining integrity
is critical.
Adaptive trial designs are often less statistically efficient than
fixed plans. To protect against all eventualities, statistical infer-
ence must consider the worst-case inflation of type I error. Inves-
tigators must be cautious about basing study design changes on
unreliable interim efficacy estimates. Such designs can also risk
sacrificing the flexibility to use emerging results from external
sources to alter key design features.
Regulators are very disturbed by changing scientific hypothe-
ses. Both the treatment and the indication must be identified.
Some methods allow changes in target population, primary
end-point and secondary end-points, while protecting against
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the experimental type I error. When modifying scientific hypoth-
eses during a trial, one is essentially testing the global hypothesis
that at least one of the treatment regimens tested affects at least
one of the proposed clinical outcomes in at least one of the iden-
tified target populations. This could lead to severe problems both
in estimating efficacy and defining the actual indication. Also the
idea of ‘seamless’ phase II/III trials was discussed. Although such
designs might seem advantageous, phase II studies must not be
slighted in dose finding and other aspects. In some cases, regula-
tors may already be requiring too little work in phase II. Further-
more, many phase II/III trials are not truly adaptive; rather, they
are designed as phase III trials in settings where adequate infor-
mation on biological activity is lacking.
It is mainly the early phases of drug development, being inher-
ently more exploratory than confirmatory, which could benefit
from flexibility in trial design. Adaptive designs are not often
used, although requests for scientific advice about them is rather
frequent.
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This presentation reflected a personal opinion about the role of
surrogates as clinical end-points. According to the Biomarkers
Definitions Working Group, a surrogate is ‘a biomarker that is
intended to substitute for a clinical end-point and is expected
to predict clinical benefit (or harm or lack of clinical benefit) based
on epidemiologic, therapeutic, pathophysiologic or other scien-
tific evidence’.1 Although overall survival is the gold standard
recognised by both the European Medicines Agency (EMEA) and
the US Food and Drug Administration (FDA) as a basis for condi-
tional (EMEA) or accelerated (FDA) approval of new anticancer
agents, surrogate end-points are often considered to be reason-
ably likely to predict clinical benefit.
WHAT IS REQUIRED FOR DRUG REGISTRATION OR APPROVAL?:
The European Union’s legal requirements for approval of a new
agent were highlighted. First, it must demonstrate a positive ben-
efit–risk ratio. Second, whenever possible, the agent should be
compared in a randomised, controlled clinical trial to a placebo
or an established treatment (as appropriate). Measures must be
taken to minimise bias and uncertainty. Authorisation will be
refused, however, if the agent’s efficacy is not substantiated or
is lacking, or if the agent is shown to be harmful.
The FDA’s International Conference on Harmonisation gener-
ated two general considerations for clinical trials that are relevant
to the use of surrogates as end-points.2,3 Confirmatory (phase III)
trials should demonstrate clinical benefit, and the primary end-
point should provide the most clinically relevant and convincing
evidence of effect based on a valid and reliable measure indicative
of treatment benefit.
Clinical end-points for approval or registration of anticancer
agents include overall, disease-free or progression-free survival
(PFS).8 PFS has generally relied on imaging or the onset or worsen-
ing of disease-related symptoms. Response, if the effect is dra-
matic, may also be a basis for approval. Tumour response is
most often based on imaging results or Response Evaluation Cri-
teria in Solid Tumours (RECIST),5 a set of standard parameters
used to document and report tumour response. Protection against
toxicity and reduction in the risk of disease can also be acceptable
bases for approval or registration. In general, patient benefit is
difficult to use as a clinical end-point because of the lack of reli-
able, reproducible instruments for measuring such factors as pal-
liation or improvement of symptoms. Quality-of-life assessments
are not presently considered as a basis for approval.
The EMEA’s experience shows that it has been quite flexible in
accepting end-points other than overall survival and PFS for
approval. Indeed, almost half of approvals are based on response
rate (Table 1). Response rate is only used as a basis for approval
when the anticancer agent demonstrates ‘dramatic activity’ in
the EMEA guideline or in situations where no established alterna-
tives exist and the prognosis is relatively homogeneous (e.g.
imatinib mesylate, Glivec) for chronic myeloid leukaemia after
failure of interferon). Overall, response rate has been an end-
point in 22 trials (47%), PFS in 16 (34%), and overall survival in 9
(19%). The experience of the FDAwith end-points other than over-
all survival was also discussed. Table 2 shows the proportions of
Table 1 – EMEA experience with various end-points used
in drug-registration trials
Indication N = 47 End-points
Hematologic 13 (28%) PFS, RR
Breast 13 (28%) OS, PFS, RR
Sarcoma 5 (11%) RR
Lung cancer 5 (11%) OS
Colorectal 3 (6%) OS, RR
Brain cancer 3 (6%) OS, PFS, RR
Ovarian 3 (6%) PFS, RR
Head and neck 1 (2%) RR
Prostate 1 (2%) OS
PFS, progression-free survival; RR, response rate; OS, overall
survival.
Table 2 – FDA experience with various end-points used
in clinical trials in support of accelerated or regular
approval
Accelerated (%) Regular (%)
Response rate 93 53
Time to progression 7 20
Symptom benefit 0 12
Other 7 32
Columns do not total 100% due to multiple end-points.
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